What Климадинон Treats: Main Uses and Benefits

The primary therapeutic use of this agent is to provide symptomatic support for women experiencing the climacteric period, addressing symptoms related to systemic imbalance. The medication is traditionally applied in clinical settings that involve vasomotor complaints such as hot flushes and profuse sweating, and associated neuro-psychological complaints like nervousness and irritability.

---

This phytotherapeutic option is commonly used across conditions involving episodic or fluctuating manifestations, and may be relevant for easing symptoms when they become more noticeable. It supports the easing of the symptom load of these manifestations, which contributes to easing the overall symptom load during symptomatic periods. It is relevant in therapeutic contexts where women in the perimenopausal and postmenopausal phases seek a non-hormonal option.

“This supportive therapy is used to assist with easing recurring vasomotor and neuro-psychological symptoms that may interfere with daily comfort.”

Quick Fact: Symptomatic Support for Vasomotor and Neuro-Psychological Complaints

Regulatory References

1. European Medicines Agency monograph

This section outlines the official eligibility and non-eligibility rules for Климадинон, an herbal medicinal product containing Cimicifuga racemosa (Black Cohosh) extract, as documented in authoritative government regulatory sources.

Contraindications and Absolute Exclusions

Population Status	Eligibility Rule
Hypersensitivity	Contraindicated for patients with a known allergy to the active substance or any other ingredient in the product.
Pregnancy	Contraindicated / Not Recommended due to the absence of sufficient safety data.
Lactation (Breastfeeding)	Not Recommended in the absence of sufficient data to establish safety.

Age and Comorbidity Restrictions

Population Group	Eligibility Restriction
Children and Adolescents (Under 18 years)	Use Not Intended or established for this age group for the specified indication.
Liver Disorders	Must consult a doctor before use. Patients must stop taking the medicine immediately if they develop signs suggestive of liver injury (e.g., severe fatigue, yellowing of skin or eyes, severe upper stomach pain).
Hormone-Dependent Tumours	Patients treated for or undergoing treatment for breast cancer or other hormone-dependent tumours should not use without medical advice.
Women of Childbearing Potential	Should consider using effective contraception during the course of treatment.

Use is restricted for individuals with pre-existing conditions that require professional medical evaluation, such as liver disorders, due to the need for monitoring. The overall regulatory profile defines the allowed population as adult women who do not fall into the contraindicated categories and who adhere to the restrictions for conditional use.

Interactions with other medicines and products

Official regulatory information regarding interactions with products containing Cimicifuga racemosa rhizome, the active ingredient in Климадинон, is structured around specific risk-mitigation precautions. Formal interaction studies are often stated as having not been performed.

---

Official Regulatory Constraints

Category	Constraint or Precaution
Hormonal Agents	Co-administration with oestrogens (estrogens) is a conditional restriction and should not occur unless specifically advised by a healthcare provider.
Hepatotoxic Agents	Caution is required regarding concomitant use with other medicines known to be hepatotoxic (toxic to the liver). This precaution is due to a theoretical additive risk of liver adverse events.
Alcohol	Use is constrained by the general precaution regarding other hepatotoxic agents, meaning alcohol should be avoided during treatment.

---

Population and Procedural Constraints

Official labeling identifies a population-specific constraint: patients with a history of liver disorder require increased caution, and some authorities advise against the use of the herb in this population without strict medical oversight. No mandatory timing separation rules (e.g., administering doses a certain number of hours apart) are specified in the official regulatory documents. These established regulatory constraints define the product’s official interaction profile, focusing on patient safety where formal interaction data may be limited.

Central Neurotransmitter Pathway Modulation

This domain covers how the extract interacts with specific serotonin receptor subtypes (e.g., 5-HT1A) in the brain's thermoregulatory center (hypothalamus). This action modulates key neurotransmitter signaling, influencing the activity of vasomotor pathways.

---

Selective Neuroendocrine Regulation

This mechanism addresses the potential tissue-selective influence of the drug's components on estrogen receptors in certain non-reproductive tissues, such as the CNS and bone. By engaging mechanisms that regulate hormonal signaling specifically in these areas, it influences signaling within neuroendocrine regulatory centers through selective receptor engagement, limiting agonistic effects on peripheral reproductive tissues.

---

Anti-Inflammatory and Cytoprotective Actions

The components in the extract engage mechanisms that limit cellular damage and stress by inhibiting the production of certain inflammatory mediators and neutralizing reactive oxygen species (ROS). This action affects molecular cascades that involve the generation of inflammatory mediators and reactive oxygen species, resulting in altered mediator activity.

Official Administration Guidelines for Климадинон (Cimicifuga racemosa Extract)

This section outlines the administration of the herbal preparation, focusing strictly on how the product is to be used. It does not contain information on therapeutic use, safety, or benefits.

---

Administration Scope	Detail
Route of Administration	Oral (by mouth) in solid dosage forms (e.g., tablets).
Age-Group Rules	Intended for use in adult women. There is no relevant indication for use in men, children, or adolescents.
Frequency and Timing	The daily dose is typically administered once or twice a day, depending on the specific product formulation. Solid preparations (tablets) should be swallowed and not sucked.
Preparation Requirements	No explicit preparation (e.g., dilution or shaking) is documented for solid oral dosage forms.
Missed-Dose Instructions	Take the missed dose as soon as possible, unless it is almost time for the next scheduled dose. Do not take a double dose to make up for a missed one.
Duration of Use	The preparation should not be taken for more than 6 months without professional medical advice. Consultation is required if symptoms persist or worsen during use.

---

Official Dosing Schedule

The dosage is based on the quantity of herbal substance extract, which varies by preparation type (solvent, drug-to-extract ratio, and pharmaceutical form). The daily dose for an extract corresponds to approximately 40 mg of the herbal substance (Cimicifuga racemosa rhizome).

Example Daily Dose (Extract)	Corresponds to Herbal Substance
5.6 mg of Extract 'A' (divided into 2 daily doses)	40 mg (approx.)
6.5 mg of Extract 'B' (1 single daily dose)	40 mg (approx.)

Note on Consistency: Users must follow the dosing instructions provided in the official product leaflet for the specific formulation they are using, as daily milligram doses of the extract itself can differ while remaining equivalent to the target quantity of the crude drug.

Overview of Clinical Evidence

Климадинон (Cimicifuga racemosa extract, also known as Black Cohosh) is authorized for relieving menopausal symptoms. Clinical research has long focused on whether specific extracts from this plant can modulate symptoms associated with menopause, such as hot flashes and profuse sweating.

Evidence from clinical trials investigating the effects of Black Cohosh extract remains varied. Some systematic reviews and randomized controlled trials (RCTs) indicate that certain standardized preparations are associated with a reduction in the severity of neurovegetative symptoms, while other reviews have concluded that there is not enough compelling evidence to establish clear superiority over placebo.

Key Research Findings

Symptom Group	Study Findings (General)	Notes
Vasomotor Symptoms (Hot flashes, sweating)	Studies documented improvements in the frequency and intensity of symptoms in participants taking the extract compared to baseline measurements.	This area shows the most documented shift in patient-reported severity across multiple trials.
Neurovegetative Symptoms (Sleep disturbance, nervousness)	Some research suggested concurrent improvements in sleep quality and related psychological complaints.	Improvements may be secondary to better management of hot flashes, which interfere with sleep.

Safety and Regulatory Status

The isopropanolic extract found in some authorized medicinal products is the most extensively studied Black Cohosh preparation. Regulatory agencies, including the European Medicines Agency (EMA), have issued monographs concluding a positive benefit–risk ratio for certain Cimicifuga racemosa preparations in alleviating climacteric symptoms.

Reported adverse events in clinical studies are generally mild and may include gastrointestinal discomfort or nausea. Decisions regarding the use of this, or any, treatment should be made following consultation with a healthcare provider who can evaluate individual medical history and needs.

Common questions about Климадинон (FAQ)

---

Q: What is Климадинон used for?

Климадинон is traditionally used for relieving menopause symptoms such as hot flashes and excessive sweating. It contains an extract from the black cohosh root. The specific traditional uses may vary based on local regulatory approvals.

---

Q: How long does it take for Климадинон to start working?

The onset of action for products containing black cohosh extract, like Климадинон, is generally not immediate. Significant improvement may be observed after several weeks of consistent use. You should consult the patient information leaflet or discuss expected timelines with a healthcare provider.

---

Q: Can I take Климадинон if I am pregnant or breastfeeding?

Based on available regulatory information, Климадинон is not recommended for use during pregnancy or breastfeeding. It is essential to consult a healthcare professional before using any medicine or herbal product if you are pregnant, planning to become pregnant, or breastfeeding.

---

Q: Does Климадинон interact with other medicines?

As with many herbal products, there is a potential for interactions. It is important to inform your doctor or pharmacist about all other medications and supplements you are currently taking to avoid any potential risks or reduce effectiveness. This includes prescription, over-the-counter, and other herbal remedies.

Storage and Handling Requirements

To ensure product stability and safety, Климадинон (Klimadynon) must be stored according to specific regulatory requirements. It is essential to keep the product out of the reach of children at all times.

Key storage conditions include:

• Temperature: Store at a temperature not higher than 25°C (77°F).
• Protection: The product must be protected from light.
• Packaging: Keep the medication in the original packaging until use.

Disposal

No specific hazardous-waste or environmental disposal instructions are documented in the labeling. Patients should follow standard procedures by consulting a healthcare provider or pharmacist regarding proper disposal methods for any unused or expired medication. Do not dispose of this medication via household trash or wastewater unless specifically instructed to do so by local waste management regulations or a qualified professional.